Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3,607 | 7 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan Inc. | $3,607 | 7 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $630.00 | 1 | Allergan Inc. ($630.00) |
| 2017 | $2,977 | 6 | Allergan Inc. ($2,977) |
All Payment Transactions
7 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2019 | Allergan Inc. | — | — | Cash or cash equivalent | $630.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder | ||||||
| 11/28/2017 | Allergan Inc. | — | — | In-kind items and services | $1,217.97 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder | ||||||
| 11/28/2017 | Allergan Inc. | — | — | In-kind items and services | $1,004.02 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder | ||||||
| 11/28/2017 | Allergan Inc. | — | — | In-kind items and services | $713.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder | ||||||
| 11/28/2017 | Allergan Inc. | — | — | In-kind items and services | $30.11 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder | ||||||
| 11/28/2017 | Allergan Inc. | — | — | In-kind items and services | $6.11 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder | ||||||
| 11/28/2017 | Allergan Inc. | — | — | In-kind items and services | $6.11 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients with Major Depressive Disorder | Allergan Inc. | $3,607 | 7 |
About Dr. Gihyun Yoon, M.D
Dr. Gihyun Yoon, M.D is a Psychiatry healthcare provider based in Minneapolis, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336223767.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gihyun Yoon, M.D has received a total of $3,607 in payments from pharmaceutical and medical device companies, with $630.00 received in 2019. These payments were reported across 7 transactions from 1 company. The most common payment nature is "" ($3,607).
Practice Information
- Specialty Psychiatry
- Location Minneapolis, MN
- Active Since 10/24/2006
- Last Updated 07/16/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1336223767
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Minneapolis
Dr. Sophia Vinogradov, Md, MD
Psychiatry — Payments: $33,782
Dr. John Simon, M.d, M.D
Psychiatry — Payments: $33,198
Ziad Nahas, Md, MD
Psychiatry — Payments: $21,831
Dr. Alik Widge, M.d., Ph.d, M.D., PH.D
Psychiatry — Payments: $13,727
Dr. Brian Johns, Md, Mfa, MD, MFA
Psychiatry — Payments: $6,599
Nisha Fernandes
Psychiatry — Payments: $2,051